Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVX-02 + Nivolumab in Resected Melanoma
NCT04455503Phase 2Terminated
- Sponsor
- Evaxion
- Start
- Jul 2020
- Primary completion
- Feb 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of EVX-02 in melanoma, sponsored by Evaxion. Started Jul 2020; status: terminated.
02
Drugs
EVX-02
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04455503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04455503.